2Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia, 1983,24(2) :326-329.
3Lauritzen T, Faber OK, Binder C. Variation in 1251-insuli absorption and blood glucose concrntration. Diabetologia, 1979, 5(2);291-295.
4Diabetes Control and Complication Trial Research Group(DCCT): Lifetime Benefits and Costs of Intensive. JAMA,1996,276(6): 1409-1415.
二级参考文献7
1Biackshear PJ,Rohde TD,Prosl F,etal.The implantable infusion pump:a new concept in drug delivery.Med ProgTechnol,1979,6:149
2DCCT Research Group.Epidemiology of severe hypoglycemia in the Diabetes Control andComplications Trial.Am J Med,1991,90:450-459
3DCCT Research Group.Reliabitility and validity of a diabetes quality of lifemeasure for the Diabetes Control and Complication Trial.Diabetes Care,1988,11:725-732
4Diabetes Control and Complication Trial Research Group.The effect of intensivetreatment of diabetes on the development and progression of long-term complication ininsulin-dependent diabetes mellitus.N Engl J Med,1993,329:977-986
5Mecklenburg RS,Benson JW Jr,Becker NM.Clinical use of the insulin infusion pump in100 patients with type I diabetes.N Engl J Med,1982 Aug,307:9,513-518
6Saudek CD,Duckworth WC,Giobbie-Hurder A,et al.Implantable insulin pumpusmultiple-dose insulin for non-insulin-dependent diabetes mellitus:a randomized clinicaltrial.Department of Veterans Affairs Implantable Insulin Pump Study Group [seecomments].JAMA,1996;276(16):1322-1327
